ArticleRevista da Associacao Medica Brasileira (1992)2026
Early phase (day 1-day 3) profile and clinical significance of circulating miR-101 and miR-146a in adult sepsis.
Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to investigate serum miR-101 and miR-146a expression levels in adult sepsis, compare them with healthy controls, and assess their relationships with inflammatory markers and disease severity.
methodsIn total, 15 adults meeting Sepsis-3 criteria and 15 healthy controls were prospectively enrolled. Serum miR-101 and miR-146a levels were quantified by quantitative polymerase chain reaction within 24 h using the 2-∆Ct method and reassessed on day 3. Associations with clinical, laboratory, and disease severity parameters were analyzed.
resultsOn day 1, miR-101 expression was significantly higher in the sepsis group than in controls (1.17 vs. 0.14; p=0.011). miR-146a levels were lower in sepsis but did not differ significantly (p=0.152). Neither miRNA showed a significant change from day 1 to day 3 (miR-101: p=0.776; miR-146a: p=0.191). miR-101 demonstrated positive correlations with procalcitonin, white blood cell count, C-reactive protein, creatinine, and a negative correlation with albumin. Levels were markedly higher in patients with cardiovascular comorbidities (ρ=0.622; p=0.013). miR-101 correlated positively with Acute Physiology and Chronic Health Evaluation II (ρ=0.412; p=0.024), while no association was observed with Sequential Organ Failure Assessment. miR-146a showed no meaningful correlations with clinical or laboratory parameters.
conclusionmiR-101 is significantly elevated in adult sepsis and reflects systemic inflammatory burden and disease severity; however, given its limited specificity, it should be considered a complementary biomarker rather than a standalone diagnostic or prognostic tool. Its stable expression between days 1 and 3 suggests a sustained early phase molecular response. miR-146a shows no significant change and has limited diagnostic relevance in adult sepsis. Larger multicenter studies are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.